Poulikos I Poulikakos

List of Publications by Year
in descending order

24	2,882	394421 19	713466 21
papers	citations	h-index	g-index

24	24	24	5910
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ROCK1 mechano-signaling dependency of human malignancies driven by TEAD/YAP activation. Nature Communications, 2022, 13, 703.	12.8	31
2	Molecular Pathways and Mechanisms of BRAF in Cancer Therapy. Clinical Cancer Research, 2022, 28, 4618-4628.	7.0	37
3	Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. Cancer Discovery, 2021, 11, 1716-1735.	9.4	30
4	Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. Nature Cancer, 2021, 2, 429-443.	13.2	29
5	BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nature Medicine, 2021, 27, 851-861.	30.7	38
6	AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathwayâ€“Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B. Cancer Discovery, 2021, 11, 3064-3089.	9.4	32
7	Abstract 41: Tumor resistance to CDK4/6 inhibitors and degraders determined by the expression state of CDK6. , 2021, , .		0
8	Triple MAPK Inhibition Salvaged a Relapsed Post BCMA CAR-T Cell Therapy in Multiple Myeloma Patient with BRAF V600E Dominant Clone. Blood, 2021, 138, 4720-4720.	1.4	0
9	Inhibitors of BRAF dimers using an allosteric site. Nature Communications, 2020, 11, 4370.	12.8	48
10	Mouse ER+/PIK3CAH1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents. Oncogene, 2019, 38, 47-59.	5.9	20
11	Global view of the RAF-MEK-ERK module and its immediate downstream effectors. Scientific Reports, 2019, 9, 10865.	3.3	12
12	SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors. Cell Reports, 2019, 26, 65-78.e5.	6.4	146
13	RAF/MEK/extracellular signalâ€“related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. Journal of Experimental Medicine, 2018, 215, 319-336.	8.5	58
14	A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, TPS1103-TPS1103.	1.6	1
15	Reconstructing the Clonal and Mutational Architecture of Myeloma through Avian Leukosis Virus (ALV)-Mediated Genome Editing. Blood, 2018, 132, 4480-4480.	1.4	0
16	New perspectives for targeting RAF kinase in human cancer. Nature Reviews Cancer, 2017, 17, 676-691.	28.4	285
17	Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma. Oncotarget, 2017, 8, 46065-46070.	1.8	24
18	Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood, 2016, 128, 2533-2537.	1.4	122

#	Article	IF	Citations
19	An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer Cell, 2016, 30, 485-498.	16.8	130
20	Personalized Preclinical Trials in BRAF Inhibitorâ€“Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clinical Cancer Research, 2016, 22, 1592-1602.	7.0	108
21	Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing. Nature Communications, 2015, 6, 7103.	12.8	100
22	BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell, 2015, 28, 370-383.	16.8	392
23	Targeting RASâ€“ERK signalling in cancer: promises and challenges. Nature Reviews Drug Discovery, 2014, 13, 928-942.	46.4	887
24	Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood, 2014, 124, 3007-3015.	1.4	352